Compare CUBI & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | AMPH |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | 790 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.3B |
| IPO Year | 2012 | 2014 |
| Metric | CUBI | AMPH |
|---|---|---|
| Price | $73.75 | $25.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $84.14 | $31.00 |
| AVG Volume (30 Days) | 291.5K | ★ 374.8K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.96 | 2.27 |
| Revenue | $651,983,000.00 | ★ $723,305,000.00 |
| Revenue This Year | $16.77 | $1.35 |
| Revenue Next Year | $6.91 | $5.10 |
| P/E Ratio | $14.71 | ★ $11.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.75 | $20.39 |
| 52 Week High | $73.94 | $45.39 |
| Indicator | CUBI | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 68.83 | 46.74 |
| Support Level | $69.00 | $25.20 |
| Resistance Level | $74.57 | $26.50 |
| Average True Range (ATR) | 1.96 | 0.82 |
| MACD | 0.42 | -0.17 |
| Stochastic Oscillator | 88.43 | 19.97 |
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.